Xeris Biopharma Holdings, Inc./$XERS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Ticker
$XERS
Sector
Primary listing
Employees
394
Headquarters
Website
XERS Metrics
BasicAdvanced
$1.5B
-
-$0.21
0.86
-
Price and volume
Market cap
$1.5B
Beta
0.86
52-week high
$9.41
52-week low
$3.59
Average daily volume
2.3M
Financial strength
Current ratio
1.95
Quick ratio
1.18
Long term debt to equity
-1,300.596
Total debt to equity
-1,332.485
Interest coverage (TTM)
-0.08%
Profitability
EBITDA (TTM)
8.381
Gross margin (TTM)
82.24%
Net profit margin (TTM)
-13.01%
Operating margin (TTM)
-1.51%
Effective tax rate (TTM)
9.41%
Revenue per employee (TTM)
$620,000
Management effectiveness
Return on assets (TTM)
-0.70%
Return on equity (TTM)
165.84%
Valuation
Price to revenue (TTM)
5.662
Price to book
-76.37
Price to tangible book (TTM)
-10.85
Price to free cash flow (TTM)
-83.025
Free cash flow yield (TTM)
-1.20%
Free cash flow per share (TTM)
-0.11
Growth
Revenue change (TTM)
35.62%
Earnings per share change (TTM)
-50.27%
3-year revenue growth (CAGR)
45.50%
3-year earnings per share growth (CAGR)
-43.95%
Bulls say / Bears say
Total revenue in Q2 2025 rose 48.8% year-over-year to a record $71.5 million, driven by a 135.7% increase in Recorlev® net revenue, underscoring strong commercial momentum (Business Wire).
Xeris raised its full-year 2025 revenue guidance to $280–$290 million—up from $260–$275 million—reflecting confidence in sustained product demand and long-term growth prospects (Business Wire).
The FDA approval and upcoming launch of Gvoke VialDx™ in partnership with American Regent expands Xeris’s portfolio into diagnostic applications, diversifying revenue streams beyond endocrine therapies (Investing.com).
Keveyis® net revenue fell approximately 12.5% year-over-year in Q2 2025 as product shipments declined, signaling challenges in sustaining growth for Xeris’s legacy rare disease therapy (Business Wire).
Xeris ended Q4 2024 with $71.6 million in cash—having generated just $2 million during the quarter—raising concerns over its near-term liquidity given ongoing R&D and commercialization investments (Business Wire).
Two directors resigned in March 2025 and the board will shrink to eight members after the Annual Meeting, potentially disrupting governance continuity during a critical growth phase (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
XERS News
AllArticlesVideos
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
Business Wire3 days ago
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire3 weeks ago
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xeris Biopharma Holdings, Inc. stock?
Xeris Biopharma Holdings, Inc. (XERS) has a market cap of $1.5B as of October 26, 2025.
What is the P/E ratio for Xeris Biopharma Holdings, Inc. stock?
The price to earnings (P/E) ratio for Xeris Biopharma Holdings, Inc. (XERS) stock is 0 as of October 26, 2025.
Does Xeris Biopharma Holdings, Inc. stock pay dividends?
No, Xeris Biopharma Holdings, Inc. (XERS) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Xeris Biopharma Holdings, Inc. dividend payment date?
Xeris Biopharma Holdings, Inc. (XERS) stock does not pay dividends to its shareholders.
What is the beta indicator for Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings, Inc. (XERS) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.